Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subglottic cysts: The Great Ormond Street experience in 105 patients.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2020
Same author

Analysis of intensive care admissions among paediatric obstructive sleep apnoea referrals.

Annals of the Royal College of Surgeons of England·2017
Same author

Safe balloon sizing for endoscopic dilatation of subglottic stenosis in children.

The Journal of laryngology and otology·2017
Same author

[Extended coronary dissection caused by severe polytrauma with contusio cordis : Venoarterial ECMO-assisted percutaneous coronary intervention].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2015
Same author

Nasal dermoids in children: a proposal for a new classification based on 103 cases at Great Ormond Street Hospital.

International journal of pediatric otorhinolaryngology·2014
Same author

The first International Standard anti-Brucella melitensis Serum.

Revue scientifique et technique (International Office of Epizootics)·2012
Same journal

Establishment of a rat model of bronchopulmonary dysplasia complicated with pulmonary hypertension and its potential applications.

Human & experimental toxicology·2026
Same journal

Pulmonary iron oxide (Fe<sub>3</sub>O<sub>4</sub>) nanoparticle-biomolecule interactions modified during aging and metabolic syndrome disease progression.

Human & experimental toxicology·2026
Same journal

Retraction: Carvedilol alleviates the detrimental effects of azathioprine on hepatic tissues in experimental rats: Focusing on redox system, inflammatory and apoptosis pathways.

Human & experimental toxicology·2026
Same journal

Inhibition of store-operated calcium entry mitigates lipopolysaccharide-induced hepatotoxicity via modulating inflammatory and oxidative stress responses.

Human & experimental toxicology·2026
Same journal

Stevioside inhibits colorectal cancer progression by regulating macrophage polarization.

Human & experimental toxicology·2026
Same journal

Predictive factors of severe outcome in glufosinate ammonium poisoning: A retrospective study in Vietnam.

Human & experimental toxicology·2025
See all related articles

Related Experiment Video

Updated: May 17, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Single-agent duloxetine ingestions.

J Jacob1, D Albert, K Heard

  • 1Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO 80201, USA. jeena2010.jj@gmail.com

Human & Experimental Toxicology
|November 1, 2012
PubMed
Summary
This summary is machine-generated.

Duloxetine ingestions are generally benign in children and adults. Most symptomatic cases involve neurological, gastrointestinal, and cardiovascular effects, with most pediatric patients managed outside healthcare facilities.

Related Experiment Videos

Last Updated: May 17, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Area of Science:

  • Pharmacology
  • Toxicology
  • Pediatrics

Background:

  • Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is primarily prescribed for depression.
  • Understanding the clinical effects of duloxetine ingestions is crucial for risk assessment and management.

Purpose of the Study:

  • To analyze the demographic and clinical outcomes of duloxetine ingestions.
  • To identify common adverse effects and management strategies across different age groups.

Main Methods:

  • Retrospective analysis of duloxetine exposure data from the National Poison Data System (NPDS) between 2004 and 2010.
  • Categorization of 11,373 patients into three age groups: ≤6 years, 7-12 years, and >12 years.
  • Evaluation of reported neurological, cardiovascular, and gastrointestinal effects.

Main Results:

  • Neurological effects increased with age (6.1% in ≤6 years to 24.6% in >12 years).
  • Cardiovascular effects also rose with age (1.4% in ≤6 years to 11.6% in >12 years).
  • Gastrointestinal effects were most prevalent in the 7-12 year group (16.6%). Common symptoms included tachycardia, nausea, vomiting, agitation, dizziness, and drowsiness.
  • Most pediatric patients (≤12 years) were managed non-institutionally, while older patients (>12 years) were more frequently referred to healthcare facilities.

Conclusions:

  • Duloxetine ingestions are predominantly benign in both pediatric and adult populations.
  • Neurological, gastrointestinal, and cardiovascular symptoms are the most common clinical manifestations.
  • The majority of pediatric duloxetine ingestions can be safely managed in non-healthcare settings.